Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Open original source
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Open original source